Pentagon awards Cardinal Health $1.5 billion medical contract
Key Facts
The U.S. Department of Defense awarded Cardinal Health a $1.5 billion government contract under the “Medical-Surgical Prime Vendor” program, according to a report published by Dow Jones on October 27 and carried by MarketScreener. The program covers the supply of medical and surgical products, according to details in the department’s announcement. The contract places the company among a group of companies that won six contracts under the program, according to the announcement. Earlier wording had combined Cardinal Health’s awards into one contract, while corrections indicated that the company received three separate contracts. The announcement did not describe the awards as drug distribution contracts.
The contracts fall under multi-year, indefinite-delivery agreements, with a time limit extending through 2029, according to details in the department’s announcement. The contract’s value or ceiling does not mean the full amount will be recorded as company revenue, as performance is tied to actual orders. The announcement alone therefore does not establish the amount of revenue that will be realized or when it will be recorded. In the context of the two companies’ commercial activity, Pharmaceutical Commerce reported that an extension of the distribution agreement with CVS Health is targeted for June 2032. McKesson’s agreement covers CVS retail, mail-order and specialty pharmacies, as well as distribution centers.
The companies’ shares closed at their levels recorded on October 26, at $251.54 for Cardinal Health and $992.87 for McKesson, according to EL7 data. These prices provide a market snapshot preceding the contract report, and the available evidence does not include a daily comparison or price movement attributed to the announcement. On the financial front, Cardinal Health said revenue in the fourth quarter of its fiscal 2026 rose 6% to $63.7 billion. This provides context predating the contract and does not determine the award’s effect on the company’s future results. The company is scheduled to report first-quarter fiscal 2027 results on November 5.
Markets are also awaiting McKesson’s second-quarter fiscal 2027 results, scheduled for release on November 4, according to the company’s investor relations page. The date comes after the government contract announcement but one day before Cardinal Health reports results. The upcoming releases will provide an update on the companies’ performance in two different fiscal periods. The CVS agreement extension adds a commercial context spanning years alongside the announced government contracts. The amount realized from those contracts remains tied to orders fulfilled under the indefinite-delivery mechanism.